银屑病关节炎与肥胖:临床负担综述及综合管理考量
本文为叙述性综述,非系统性检索PubMed、Embase和Scopus数据库,分析银屑病关节炎(PsA)与肥胖的相互作用。肥胖通过全身炎症、脂肪因子失调和机械关节应力加重PsA,导致更差的临床结局、更多合并症及生物制剂反应不佳。体重管理可改善疾病活动度和疗效,但指南推荐协调护理方法,仍需进一步研究。
要点
- 肥胖是PsA的风险因素和合并症,应纳入整体管理。
- 肥胖通过炎症、脂肪因子和机械应力加重PsA并降低生物制剂反应。
- 体重管理可改善疾病活动度和疗效,但机制未充分探索。
核心结论
- 肥胖应被视为PsA的风险因素和合并症以进行整体管理。
- 体重管理可改善疾病活动度和治疗疗效,但对PsA病理生理的影响尚待探索。
研究设计与样本
- 本文为叙述性综述,采用非系统性检索PubMed、Embase和Scopus数据库。
- 文献分析优先纳入临床试验、荟萃分析和大型队列研究。
主要发现
- 肥胖通过全身炎症、脂肪因子失调和机械关节应力加重PsA。
- 肥胖 contribute 至更差的临床结局、增加的合并症和对生物制剂更差的反应。
- 体重管理改善疾病活动度和治疗疗效。
临床怎么用
- 临床指南推荐采用协调护理方法优化肥胖PsA患者的管理。
- 新兴临床数据支持进一步关注靶向炎症、肥胖和代谢功能障碍以改善长期结局。
局限性
- 体重管理对PsA病理生理的影响尚未充分探索。
- 需要进一步研究阐明体重管理诱导的细胞因子和分子变化并生成更多临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterised by joint involvement, significant impact on quality of life and frequently linked with obesity, metabolic syndrome and cardiovascular comorbidities. Despite advances in PsA management, obesity remains a critical factor influencing disease severity, treatment response and patient outcomes. We examine the interplay between PsA and obesity, the current clinical guidelines, gaps in clinical practice, research on shared inflammatory pathways, treatment implications and the potential of weight-loss interventions to modify disease progression. This comprehensive narrative review uses a non-systematic search of PubMed, Embase and Scopus databases and analyses literature on PsA, obesity, cytokine signalling and therapeutic outcomes, with priority to clinical trials, meta-analyses and large cohort studies. Obesity exacerbates PsA through systemic inflammation, adipokine dysregulation and mechanical joint stress, contributing to worse clinical outcomes, increased comorbidity and poorer response to biologics. Weight management improves disease activity and therapeutic efficacy, although its effects on PsA pathophysiology remain underexplored. Our review highlights that obesity should be recognised as a risk factor and comorbidity in PsA for the integral management of patients. Further research is needed to elucidate the cytokine and molecular changes induced by weight management, generate more clinical data and optimise personalised management strategies. While clinical guidelines recommend a coordinated care approach to optimising the management of PsA in patients with obesity, emerging clinical data support further focus on the role of targeting inflammation, obesity and metabolic dysfunction to improve long-term PsA outcomes and quality of life, mitigate complications and provide better cardiovascular and overall health to patients.
引用
- Madsen N, Coates LC, Merola JF, et al. Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive care. RMD Open. 2026. PMID: 42457215. doi:10.1136/rmdopen-2025-006577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。